The role of HBsAg quantification for monitoring natural history and treatment outcome

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 125-132

  Martinot Peignoux, Michelle ^a   Lapalus, Martine ^a   Asselah, Tarik ^a   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Analogues; Hepatitis B virus tools; Pegylated IFN; Personalized medicine; Prediction; Prognosis

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON; VIRUS DNA;

HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; NONHUMAN; PROTEIN BLOOD LEVEL; REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DNA, VIRAL; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; NUCLEOSIDES; NUCLEOTIDES; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872045830     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12075     Document Type: Review

References (74)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 118-29.
2. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-55.
3. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
4. Madalinski K, Burczynska B, Heermann KH, et al. Analysis of viral proteins in circulating immune complexes from chronic carriers of hepatitis B virus. Clin Exp Immunol 1991; 84: 493-500.
5. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-8.
6. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-13.
7. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-44.
8. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-22.
9. Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between the Elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen (HBsAg) in serum. J Clin Virol 2011; 50: 292-6.
10. Sonneveld MJ, Rijckborst V, Boucher CAB, et al. A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B. J Clin Virol 2011; 51: 175-8.
11. Liaw YF. Clinical utility of hepatitis B surface antigen quantification in patients with chronic hepatitis B: a review. Hepatology 2011; 53: 2121-9.
12. Chan HL, Wong GL, Wong VW. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14: 489-99.
13. Martinot-Peignoux M, Lapalus M, Lada O, et al. Natural history of hepatitis B (HBV) infection: role of HBV genotype (A to E) assessed in a large cohort. Hepatology 2011; 54(Suppl): 609A.
14. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-A core group report. J Hepatol 2011; 55: 1121-31.
15. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompaned by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198-202.
16. Sung JJ, Chan HL, Wong ML, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepatol 2002; 9: 229-34.
17. Martinot-Peignoux M, Boyer N, Colombat M, et al. Serum hepatitis B virus HBV DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 2002; 36: 543-6.
18. Brunetto MR, Oiveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-70.
19. Papatheodoridis GV, Manesis EK, Manalakopoulos S, et al. Is there a meaninful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B infection? Hepatology 2008; 48: 1451-9.
20. Lok As, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-53.
21. EASL clinical practice guidelines: management of chronic hepatitis B. European Association for the Study of the Liver. J Hepatol 2012; 50: 227-42.
22. Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010; 52: 1232-41.
23. Chan HL, Wong GL, Tse CH, et al. Definition of inactive hepatitis B carrer by serum HBsAg and HBV DNA levels - a long-term follow-up study on HBsAg seroclearance. J Hepatol 2011; 54: S144.
24. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-90.
25. Martinot-Peignoux M, Lada O, Cardoso AC, et al. Quantitative HBsAg: a new specific marker for the diagnosis of HBsAg inactive carriage. Hepatology 2010; 52: 992A.
26. Martinot-Peignoux M, Lapalus M, Laouénan C, et al. How to distinguish HBeAg negative chronic hepatitis B, with high risk of reactivation, from inactive carriers: is there a place for HBsAg quantification? Hepatology 2012; 56(Suppl): 434A.
27. Seto WK, Wnog DKH, Fung J, et al. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS ONE 2012; 7: e43087.
28. Martinot-Peignoux M, Carvalho RJ, Cardoso AC, et al. Significant genotype-specific association of hepatitis B surface antigen level and severity of liver disease in patients with chronic hepatitis B. Hepatology 2011; 54(Suppl): 1078A.
29. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamuvidine, and the combination for HbeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
30. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a, lamuvidine, and the two in combination for HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
31. Janssen HLA, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on α-interferon therapy. Antivir Res 1994; 23: 251-7.
32. Chan HL, Wong VW, Chim AM, et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-15.
33. Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to peginterferon alfa-2b therapy in chronic hepatitis B. J Clin Virol 2009; 46: 117-23.
34. Lau G, Marcellin P, Brunetto M. On treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2009; 50: S333.
35. Gane E, Jia J, Han K, et al. NEPTUNE study; on treatment HBs Ag level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg positive patients. J Hepatol. 2011; 54: S25-44. Abstract 69
36. Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.
37. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all HBeAg-positive patients. Hepatology 2011; 53: 1054-5.
38. Flink HJ, van Zonneveld M, Hansen B, et al. treatment with Peg-Interferon a-2a for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype? Am J Gastroenterol 2006; 101: 297-303.
39. Soneveld MJ, Rijckborst V, Cakalog-1 lu Y, et al. Durable hepatitis surface antigen decline in hepatitis B e antigen positive chronic hepatitis B patients treated with pegylated interferon-a2b: relation to response and HBV genotype. Antiviral Ther 2012; 17: 9-17.
40. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surafce antigen in hepatitis B e antigen-negative patients trated with pegylated interferon-a2a. Antiviral Ther 2009; 14: 1183-8.
41. Hadziyannis SJ. Treatment paradigms on hepatitis Be antigen-negative chronic hepatitis B patients. Expert Opin Investig Drugs 2007; 16: 777-86.
42. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
43. Rijckborst V, Hansen BE, Cakalog-1 lu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
44. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
45. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
46. Brunetto MR, Moriconi F, Bononi F, et al. Hepatitis B virus surface antigen levels: a guide to sutained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
47. Moucari R. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks. J Gastroenterol Hepatol 2010; 25: 1474-5.
48. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-92.
49. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012; 61(Suppl. 1): i18-24.
50. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alpha-2a. J Hepatol 2012; 6: 1006-11.
51. Lampertico P, Vigano P, Di Costanzo g, et al. Extended (2 years) treatment with peginterferon alfa-2a improves sustained response rates in genotype D patients with HBeAg negative chronic hepatitis B. J Hepatol 2010; 52: S45.
52. Piratvisuth T, Lau GKK, Marvellin P, et al. On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 month post-treatment in HBsAg positive hepatitisB virus-infected patients treated with peginterferon alfa-2a (40kD) (PEGASYS). Hepatol Int 2010; 4: 152.
53. Liaw YF, Jia JD, Chan HLY, et al. Shorter duration and lower doses of peginterferon alfa-2a are associated with inferior hepatitis Be antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54: 1591-9.
54. Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBaAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa 2b in HbeAg positive patients. JGH 2010; 25: 1498-506.
55. Lampertico P, Vigano M, Di Costanzo GC, et al. Response-guided peginterferon alfa-2a therapy based on HBsAg levels at week 12 and week 24 or 48 improves respose rates in HBeAg negative genotype D patients. J Hepatol 2011; 56: S207.
56. Brunetto M, Bonino F, Marcellin P, et al. Kinetics of HBsAg decline in patients with HBeAg negative chronic hepatitis B treated with peginterferon alfa 2a according to genotype and its association woth sustained HBsAg clearance. Hepatology 2008; 48(Suppl): 740A.
57. Manesis EK, Hadziyannis ES, Angelopoulou OS, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.
58. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatits B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-54.
59. Lee MH, Lee DM, Kim SS, et al. Correlation of serum hepatitis B srface antigen level with response to entecavir in naive patients with chronic hepatitis B. J Med Virol 2011; 83: 1178-86.
60. Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e atigen titers in prediction of treatment response to entecavir. Hepatology 2100; 53: 1486-93.
61. Chen J, Wang Z, Zhou B, et al. Factors associated with hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy. Antiviral ther 2012; 17: 71-9.
62. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-20.
63. Gramenzi A, Log-1 gi E, Micco L, et al. Serum hepatitis B surface antigen monitiring in long-term lamuvudine-treated hepatitis B virus patients. J Viral Hepatitis 2011; 10: 468-74.
64. Zoulim F, Carosi G, Greenbloom S, et al. Quantification of HBsAg in nucleos(t)ides-naive patients treated for chronic hepatitis B with entecavir or entecavir plus tenofovir in the BE-LOW study. J Viral Hepatitis 2012; 19(Suppl. S3): O224.
65. Bruce MJ, Horner M, Knighton S, et al. Strong decline in HBsAg levels after virological response in a large monocentric therapy cohort: potential to select HBeAg positive chronic hepatitis B patients for finite duration? Hepatology 2012; 56(Suppl): 439A.
66. Orito E, Kusakabe A, Kanie H, et al. Quantification of HBsAg predicts response to naive entrcavir therapy in chronic hepatitis B patients with genotype C. Hepatology 2012; 56(Suppl): 395A.
67. Zoutendijk R, Hansen BE, Van Vuuren AJ, Boucher CA, Janssen HL. Prediction of HBsAg loss using HBsAg decline after long-term virological response to nucleos(t)ide analogue therapy for chronic hepatitis B. Hepatology 2010; (Suppl): 509A.
68. Marcellin M, Heathcote EJ, Buti M, et al. Tenofovir disiproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
69. Heathcote EJ, Marcellin M, Buti M, et al. Three years efficacy and safety of tenofovir disiproxil fumarate treatment for chronic hepatitis B. Gastroenterrology 2011; 140: 132-43.
70. Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B after discontinuation of antiviral therapy. Aliment Pharmacol Ther 2011; 34: 344-52.
71. Petersen J, Buggischi P, Stoehr A, et al. Stopping long-term nucleos(t)ides analogue therapy before HBsAg loss or seroconversion in HBeAg negative CHB patients: experience from five referral centers in Germany. Hepatology 2011; 54(Suppl): 1417A.
72. Suh SJ, Yeon JE, Yoon EL, et al. Quantification of serum hepatitis B surface antigen as a predictor of off-treatment sustained virological response in in chronic hepatitis B patients treated with oral nucleos(t)ide analogue. J Hepatol 2012; 56(Suppl): S71-S204.
73. Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22-6.
74. Tseng TC, Liv CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-9.